Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Emyria.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Telix tumbles 17pc, Emyria to import MDMA after approval in Canada
Health & Biotech
Clinical results for ancient therapy help ASX cannabis stocks weed out competition
News
ASX Small Caps & IPO Weekly Wrap: ASX dips 2.2pc and everyone Torqued like a pirate at Penzance
News
Rise and Shine: Everything you need to know before the ASX opens
News
In Case You Missed It: Rare earths on the rise, and coal seam gas pilot spudded
News
ASX Small Caps Lunch Wrap: Who else is feeling the Real Estate rage today?
News
Top 10 at 11: Emyria soars on funding news, and loads of tasty stuff unearthed in Canada.
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
ASX Health Stocks: Recce Pharma jumps 20pc after saying its gel could heal antibiotic-resistant infections
Health & Biotech
How Bod Science pulled ahead in the race for Australia’s first over-the-counter CBD
News
CLOSING BELL: And just like that, all the magic was gone leaving the ASX flat today
Health & Biotech
Weed Week: Storm before the calm as cannabis market set to boom after SAFE Banking Act passed
Health & Biotech
ASX Health Stocks: Avita jumps 14pc on FDA approval; Emyria to start trial on landmark MDMA therapy
Health & Biotech
Weed Week: A ‘shroom boom’ could see psychedelics follow cannabis’ explosive footsteps
Health & Biotech
Could these Aussie psychedelics stocks carve a slice out of a ‘potential $63 billion’ global market?
News
CLOSING BELL: Nobody’s quite game to pick the bottom after the ASX makes it 5 losses on the trot
Health & Biotech